OSLO, 30 May 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX), a
clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces that Intellectual
Property Office in United Kingdom yesterday announced the issuance of UK Patent
No. GB2595513 entitled "Treatment of infections".

The granted patent claims cover EXACT-Tx's unique microbubble/ microdroplet
formulation (PS101) and its use, co-administered with a range of pharmaceutical
agents for ultrasound mediated drug targeting for treatment of infections. This
is an important step in securing EXACT-Tx's mission to enhance the therapeutic
outcome of the standard of care across drug classes for the benefit of patients
across diseases. 

For more information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®).  ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com

About ACT®:
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas and product classes. 

Forward looking statements:
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.